But the benefits resulting from MEDICA and COMPAMED went far beyond capital acquisition for the start-up: “The trade fair was a success for us in many ways. In addition to the attention it generated, it also brought us directly into contact with suitable suppliers – a real bonus given the complexity of our product,” said Quentin François, Chief Product Officer. The micro-robot consists of a large number of different parts that must be produced and delivered in high quality and in sufficient quantities. That is why Robeauté is currently working with suitable partners to establish a corresponding European supply chain, according to François. Clinical trials are scheduled to start in 2026, when the first patient is also expected to be treated.

Liver diagnostics on a molecular basis


Another highlight at the MEDICA START-UP COMPETITION 2024 was the U.S. start-up AGED Diagnostics, which took second place with an innovative blood test for the non-invasive diagnosis of liver disease. Through targeted sequencing of DNA and RNA changes, diseases such as NASH (non-alcoholic steatohepatitis) can be detected at an early stage. CEO Rachel Zayas stated: “The European market is very important to us – MEDICA was the perfect place to engage in direct dialogue with an international audience of experts.” Following the competition, a clinical trial involving 500 patients at nine locations in the U.S. was launched. CE marking is planned for the EU market, supported by collaborations such as the Medical Forge Leipzig start-up accelerator program. Recently completed seed financing of three million euros will enable further development of the prototype.

Neurostimulation instead of painkillers: a new approach to PMS and PMDD

The 17th HEALTHCARE INNOVATION WORLD CUP promises more presentations of groundbreaking developments in 2025, with a focus on innovations in the field of the Internet of Medical Things. Newl solutions for wearable medical devices, digital biomarkers, smart plasters and therapy systems are in demand. Last year's winner, British start-up Samphire Neuroscience, won with a revolutionary, drug-free neurostimulation device for premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD). The portable device, called ‘Nettle’, is designed to replace the use of painkillers (with undesirable side effects) and is now available throughout the EU and the United Kingdom. CEO Dr Emilė Radytė plans to participate in MEDICA again this year. According to Radytė, start-ups that already have a product or are about to launch one should take advantage of the benefits of participating in the HEALTHCARE INNOVATION WORLD CUP – the trade fair is an ideal platform for finding potential business partners.

European Press Room Homepage